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Abstract
Background: Quantification of hepatitis B virus (HBV) DNA can be used for diagnosing HBV infection and
monitoring the effect of antiviral therapy. However, probably because of mismatches between the template and
primer/probe, HBV DNA in some HBV infections could not be detected using currently available commercial assays
with single primer/probe. By aligning the HBV sequences, we developed a duplex real-time polymerase chain
reaction (PCR) assay using two sets of primers/probes and a specific armored DNA as internal control (IC).
Results: The limit of the duplex real-time PCR assay was 29.5 IU/ml, whereas the specificity was 100%. The
within-run precision coefficient of variation (CV) ranged from 1.02% to 2.73%, while the between-run CV ranged
from 0.83% to 1.25%. The optimal concentration of armored DNA IC in the HBV DNA duplex real-time PCR assay
was 1 000 copies/ml. Data from 69 serum samples with HBV infection showed that the performance of the duplex
real-time PCR assay was comparable to that of the COBAS Ampliprep/Cobas Taqman (CAP/CTM) HBV assay and
was superior to those of the domestic commercial HBV assays.
Conclusions: The duplex real-time PCR assay is sufficiently sensitive, specific, accurate, reproducible and cost-
effective for the detection of HBV DNA. It is suitable for high throughput screening and frequent HBV DNA level
monitoring.
Background
An estimated 600,000 persons worldwide die each year
due to the acute or chronic consequences of hepatitis B
caused by the hepatitis B virus (HBV) infection [1].
Nowadays, HBV infection is a leading cause of death in
China [2]. Of the 350-400 millions people with chronic
hepatitis B, a third of them live in China [3]. Serologic
tests were used routinely for the diagnosis of HBV infec-
tion. However, during the window period of hepatitis B
virus infection, early diagnosis and follow-up of infection
cannot be achieved by serologic tests. Moreover, some
studies indicate that HBV may be transmitted by indivi-
duals with occult HBV infection (OHB), that is, persons
who have no serologic evidences of ongoing HBV repli-
cation [4,5].
The best indication of active viral replication is detec-
tion of HBV DNA in plasma or serum [6-9]. Several
assays based on real-time PCR have been developed for
quantification of HBV DNA in serum or plasma samples
[10-12]. Compared to serologic tests, real-time PCR-
based assays with high sensitivity and high specificity
may allow earlier diagnosis of HBV infection [13,14].
HBV polymerase lacks proofreading activity, thus, the
mutation rate for HBV is higher than the rate observed
for most DNA viruses [15,16]. Currently there are eight
accepted genotypes (A to H) for HBV based on the
inter-group divergence of 8% or more in the complete
genome sequence [17]. High mutation rate of viral gen-
omes may results in failure to recognize increasing vire-
mia levels [18] and even miss detecting HBV DNA by
real-time PCR assay with single primer/probe because of
mismatches between the template and the primer/probe
[19,20]. Previous studies indicated that the performances
of duplex real-time reverse transcriptase-PCR assay have
been improved and could avoid missing detection of
* Correspondence: ljm63hn@yahoo.com.cn
† Contributed equally
1National Center for Clinical Laboratories, Beijing Hospital, Beijing, People’s
Republic of China
Full list of author information is available at the end of the article
Sun et al. Virology Journal 2011, 8:227
http://www.virologyj.com/content/8/1/227
© 2011 Sun et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.hepatitis C virus (HCV) and Human immunodeficiency
virus (HIV) to some extent with two sets of primer/probe
[21,22]. Similarly, a real-time PCR assay with two sets of
primer/probe may resolve the problem of mismatches
and avoid missing detections of HBV infection. However,
rare information has been published on the duplex real-
time PCR assay for HBV DNA quantification.
In addition, it is necessary to use an internal control (IC)
to monitor the specimen extraction and amplification effi-
ciency of real-time PCR assay. Compared with commonly
used plasmid IC, armored DNA produced by the lambda
phage system is DNase-resistant, stable, noninfectious,
inexpensive, and easily to be extracted and could be used
as an ideal control for clinical viral testing [23-25].
In this study we developed a duplex real-time PCR
assay with armored DNA as IC for HBV DNA detection.
The assay possesses all the performance characteristics
that make it amenable for high throughput screening of
HBV infection.
Materials and methods
Serum samples and standards
30 HBV-positive and 10 HBV-negative samples from
Beijing Blood Center (Beijing, China) were used for
comparison of the performances of singleplex primer/
probe and duplex primer/probe assays.
100 HBV-negative blood donors serum samples
including 80 healthy controls and 20 controls with hepa-
titis A, hepatitis C, hepatitis E, human immunodefi-
ciency virus type 1 infection, or human T-cell leukaemia
virus infection (confirmed at the blood bank) were
enrolled.
Furthermore, 69 serum samples were collected from
Shenzhen Blood Center (Guangdong, China). Each sam-
ple was divided into 4 aliquots and frozen at -80°C within
4 h after collection. These samples were used to compare
the performances of Kehua HBV DNA real-time PCR
detection kit (Shanghai Kehua Bio-Engineering Co. Ltd.,
Shanghai, China), qualitative duplex real-time PCR assay,
and COBAS Ampliprep/Cobas Taqman (CAP/CTM)
assay (Roche Molecular Systems, Pleasanton, CA).
A dilution series of the World Health Organization
(WHO) Second International Standard for HBV DNA
(National Institute for Biological Standards and Control
(NIBSC), code 97/750, UK) was used to determine the
limit of detection (LOD) of the duplex real-time PCR assay
at the following concentrations: 5, 10, 25, 50, 10
2,1 0
3,1 0
4
and 10
5 IU/ml. Each dilution of the WHO Standard was
tested in a batch of 4 replicates in 6 separate runs, i.e. for
each dilution, a total of 24 replicates were tested.
Selection of duplex real-time PCR primers and probes
In order to identify optimal sites for primers design, 44
HBV complete genome reference sequences representative
of all eight genotypes (A-H) downloaded from GenBank
Database were aligned using DNA star software. Gene-
Bank accession numbers of 44 HBV complete genome
reference sequences are genotypes A (AB194951,
AF090842, AJ309369, AY217375, U87742, X02763,
X51970); genotypes B (AB010292, AB031266, AB033554,
AB033555, AF100309, D00329, U87747); genotypes C
(AB014381, AB048704, AB049609, AB241110, AY123041,
X01587, X04615, X75665); genotypes D (AY090453,
M32138, V01460, X65259, X85254); genotypes E
(AB032431, DQ060823, X75657); genotypes F (AB036905,
AB036910, AB086397, AF223962, AF223965, AY090455,
X69798); genotypes G (AB064310, AF160501, AF405706);
genotypes G (AB059661, AY090454, AY090457,
AY090460). Based on the consensus sequences of the
HBV genome, two sets of primer/probe (A and B) targeting
S genes and probe for IC (ICp) were designed (Table 1). To
ensure the primers only amplify HBV DNA, they were tested
by the BLAST algorithm.
Construction and selection of optimal concentration of IC
Armored DNA was produced with the same method as
described [23]. The sequences of IC were identical to
the wild-type HBV sequences, except for the sequences
of probe Ap- and probe Bp-binding site, which were
replaced by the internal probe sequences (5’ CCCCC-
CCCCCCCCCAAAAAAAA 3’). A chequerboard assay
was performed in which the international reference
material for HBV DNA (NIBSC 97/746; 0 IU/ml, 5 × 10
2
IU/ml, 5 × 10
3 IU/ml, 5 × 10
4 IU/ml, 5 × 10
5 IU/ml)
were spiked with four different copy numbers (10
5,1 0
4,
10
3, 0) of the armored DNA. Armored DNA was
extracted and amplified with the international reference
material for HBV DNA in the same reaction tube.
Duplex real-time PCR and singleplex real-time PCR
amplification for HBV DNA detection
DNA was extracted from 100 μl sample by using extrac-
tion reagents of the Kehua HBV DNA real-time PCR
detection kit according to the manufacturer’si n s t r u c -
tions. 1.0 μl armored DNA particles (1000 copies/μl),
added to each sample prior to extraction, were used as
ICs of the extraction and amplification processes. The
final optimized PCR mixture (25 μl) contained 12.5 μl
QuantiTect Probe PCR Master Mix (QIAGEN, Quanti-
Tect Multiplex PCR kit), 1.0 μl armored DNA particles,
8 μl HBV DNA samples and the concentration of pri-
mer/probe were added as follows, in the singleplex
mode, either the primer/probe set A (0.4 μM primers,
0.4 μM probes, and 0.2 μM IC-specific probe) or the
primer/probe set B (0.4 μM primers, 0.4 μM probes,
and 0.2 μM IC-specific probe), was used in the reaction,
whereas in the duplex mode, both the primer/probe
sets A (0.4 μMp r i m e r s ,0 . 4μMp r o b e s ,a n d0 . 2μM
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and 0.2 μM IC-specific probe) were used in PCR (0.4 μM
primers, 0.4 μM probes, and 0.2 μM IC-specific probe).
PCR was performed with an ABI 7500 sequence detection
system as follows: an initial denaturation step at 95°C for
15 min, 45 cycles at 94°C for 15 s and 60°C for 1 min.
Evaluation of the duplex real-time PCR assay
To establish the linearity of HBV DNA quantification,
we prepared serial 10-fold dilutions from the HBV stan-
dard in negative serum to obtain concentrations of 10,
10
2,1 0
3,1 0
4,1 0
5,a n d1 0
6 IU/ml. Each concentration
was tested three replicates in a single run.
A set of 3 HBV positive serum samples with different
viral loads was tested 10 times in a single run to deter-
mine within-run precision coefficient of variation (CV)
in the viral quantification. Similarly, the same set of
samples was quantified in 10 different experiments to
determine between-run CV in the viral quantification.
The coefficients of variance (CV) of the threshold cycles
(Ct) were calculated.
Commercial kits for HBV DNA detection
A total of 69 serum samples were tested using Kehua
HBV DNA real-time PCR detection kit and CAP/CTM
assay kit. All the operation steps were carried out
according to the instructions given in the manuals.
(i) Detection using Kehua HBV DNA real-time PCR
detection kit. HBV DNA was extracted from 100 μl
sample, and 12.5 μle x t r a c tw a su s e da st h et e m p l a t ei n
25 μl reaction. PCR was carried out in a 32-well Light-
cycler thermal cycles system (Roche). HBV DNA levels
w e r ee x p r e s s e di nI U / m l .T h eL O Do fK e h u aH B V
DNA assay kit was 500 IU/ml.
(ii) Detection using CAP/CTM HBV assay kit. The
CAP/CTM test utilized automated specimen preparation
on the COBAS AmpliPrep Instrument by a generic
silica-based capture technique. HBV DNA was extracted
from 850 μl serum and then eluted with 65 μl of elution
buffer. Finally, 50 μl extract was used as the template in
100 μl reaction volume. The COBAS TaqMan 48
Analyzer was used for automated real-time PCR amplifi-
cation. HBV DNA levels were expressed in IU/ml. The
LOD of CAP/CTM HBV assay kit was 12 IU/ml.
Comparison the duplex primer/probe real-time PCR
assays with the singleplex primer/probe real-time PCR
assays for HBV DNA detection
The results of 30 HBV-positive and 10 HBV-negative
samples tested by singleplex primer/probe and duplex
primer/probe assays were compared.
Comparison the duplex primer/probe real-time PCR assay
with commercial kits for HBV DNA detection
69 serum samples were tested by Kehua HBV DNA
real-time PCR detection kit, qualitative duplex real-time
PCR assay, and COBAS CAP/CTM assay, the results
were then compared.
Data analysis
Results were expressed as means and standard deviation
(SD). The intra-assay and inter-assay variations were
expressed as coefficient of variation (CV), based on the
mean Ct values. Probit analysis was performed to deter-
mine the LOD. The LOD was determined as 95% prob-
ability of obtaining a positive HBV DNA result.
Correlation coefficients (R) were calculated for linearity
data.
Results
Optimal concentration of IC
To establish the optimum copy number of internal control
to be added to the tubes for HBV DNA duplex real-time
PCR assay, a chequerboard assay was performed in which
serially diluted HBV standards (5 × 10
5 to 0 IU/ml) were
spiked with four different copy numbers (10
5 to 0) of the
internal control armored DNA (Table 2). The IC copies
more than 1 000 changed the threshold cycles (Ct) for
almost all the standards which resulted in the underesti-
mation of the copy number. The optimal concentration of
armored DNA IC in the HBV DNA duplex real-time PCR
assay was 1 000 copies/ml.
Table 1 Primer and probe sequences
Primer or probe Sequence (5’-3’) Nucleotide Position
Af 5’- GTCCTCCAATTTGTCCTGG -3’ 2196-2214
Ar 5’- TGAGGCATAGCAGCAGGAT -3’ 2276-2258
Ap 5’ FAM - CTGGATGTGTCTGCGGCGTTTTATCAT - BHQ 3’ 2221-2247
Bf 5’- CACCTGTATTCCCATCCCATC -3’ 2443-2458
Br 5’- AGCCCTACGAACCACTGAACA -3’ 2559-2539
Bp 5’ FAM - AAACGGACTGAGGCCCACTCCCA -BHQ 3’ 2511-2489
ICp 5’ Cy5 - CCCCCCCCCCCCCCAAAAAAAA -BHQ 3’
Nucleotide sequence positions were numbered according to reference sequence AF090842 (genotype A). Probes for the detection of HBV DNA and IC were
labelled with 6-carboxyfluorescein (FAM) and cyanine dye (Cy5) at the 5’ end, respectively. The 3’ ends of probes were labelled with Black Hole Quencher dye
(BHQ). The length of PCR products amplified from set A and B are 81 bp and 117 bp, respectively.
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Linearity of the duplex real-time PCR assay was deter-
mined using serial 10-fold dilutions of HBV standard in
negative serum samples at the following concentrations:
10, 10
2,1 0
3,1 0
4,1 0
5,a n d1 0
6 IU/ml. Three replicates were
tested in a single run at each concentration. The propor-
tion of positive results obtained from each input concen-
tration was subjected to probit regression analysis (Table
3). The LOD of the duplex real-time PCR assay was 29.5
IU/ml (95% confidence interval, 20.9-56.2 IU/ml). Linear
regression analysis of the Ct values against the log10 HBV
DNA concentration yielded R = 0.993 (Figure 1). The spe-
cificity of the duplex real-time PCR assay was 100% when
testing HBV-negative serum samples.
The intra-assay variation was assessed by testing 3 sam-
ples with different viral loads (10
5,1 0
4,a n d1 0
2 IU/ml) 10
times in a single run, while the inter-assay variation was
assessed by testing the same samples 10 times in 10 separate
runs. The intra-assay CV ranged from 0.83% to 1.25%, while
the inter-assay CV ranged from 1.02% to 2.73% (Table 4).
Comparison the duplex primer/probe real-time PCR
assays with the singleplex primer/probe real-time PCR
assays for HBV DNA detection
40 serum samples were submitted for routine HBV
DNA testing. The duplex primer/probe assay could
strengthen the fluorescence signal of the low HBV virae-
mia samples. Figure 2 showed the performance of the
duplex primer/probe (C) and singleplex primer/probe
(A, B) assays in the testing the same low-load HBV sam-
ple. Of the confirmed 30 HBV DNA positive samples,
both singleplex primer/probe set A and set B failed to
detect 2 low HBV viraemia samples. In contrast, the
duplex primer/probe sets A+B detected all the 30 HBV-
positive serum samples (Table 5).
Comparison the duplex primer/probe real-time PCR assay
with commercial kits for HBV DNA detection
A set of 69 serum samples were tested in duplicate to
verify the validity of the duplex primer/probe real-time
PCR assay. Results obtained by the duplex real-time
P C Ra s s a yw e r ec o m p a r a b l et ot h o s eo b t a i n e db yt h e
CAP/CTM assay. Kehua HBV DNA real-time PCR assay
kit failed to detect 10 samples, which could be detected
by the duplex primer/probe real-time PCR assay and the
CAP/CTM assay (Table 6).
Discussion
In this study, we developed a novel HBV DNA quantifi-
cation system using a real-time PCR assay which
Table 2 Optimization of the concentration of IC
Armored DNA concentration
(copies/ml)
National reference
material 4 for HBV
DNA 5 × 10
5 IU/ml
National reference
material 3 for HBV
DNA 5 × 10
4 IU/ml
National reference
material 2 for HBV
DNA 5 × 10
3 IU/ml
National reference
material 1 for HBV
DNA 5 × 10
2IU/ml
HBV 0 IU/
ml
IC (Cy5)
Ct
HBV (FAM)
Ct
IC (Cy5)
Ct
HBV (FAM)
Ct
IC (Cy5)
Ct
HBV (FAM)
Ct
IC (Cy5)
Ct
HBV (FAM)
Ct
IC (Cy5)Ct
100 000 38.92 28.00 34.43 32.17 31.18 35.78 30.33 > 45 30.13
10 000 41.51 28.93 38.39 31.20 35.58 34.29 34.29 39.55 34.21
1 000 > 45 23.14 38.35 26.44 37.72 29.23 35.68 32.67 35.47
0 > 45 23.21 > 45 26.11 > 45 29.14 > 4 5 32.82 > 45
Concentrations of HBV DNA and armored DNA were indicated by FAM and Cy5 signals, respectively.
Table 3 Limit of detection of the duplex real-time PCR
assay
HBV load (IU/ml) Positive results/total tested Positive results (%)
10
5 24/24 100
10
4 24/24 100
10
3 24/24 100
10
2 24/24 100
50 24/24 100
25 22/24 91.6
10 12/24 50.0
5 5/24 20.8
Figure 1 Linearity of the duplex real-time PCR assay.L i n e a r i t y
of the duplex real-time PCR assay was determined using serial
10-fold dilutions of HBV standard in negative serum samples at the
following concentrations: 10, 10
2,1 0
3,1 0
4,1 0
5, and 10
6 IU/ml. Three
replicates were tested in a single run at each concentration. Linear
relationship between the Ct values and the log10 HBV DNA
concentration in the samples at concentrations from 10 to
106 IU/ml yielded R = 0.993.
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DNA as internal control in a single reaction tube. The
primers and two FAM labelled probes were designed
corresponding to the highlyc o n s e r v e dH B VSg e n e .
Compared with the singleplex primer/probe real-time
PCR assay, the performance of duplex real-time PCR
assay was remarkably improved and could avoid missing
detection of HBV DNA to maximum extent with two
sets of primer/probe.
The efficacy and accuracy of real-time PCR largely
depend on the primers and probe [26]. It has been
reported that several commercial HCV assays using a sin-
gleplex primer/probe set produce false-negative results
because of mismatches between the template and primers/
probes [27,28]. Similarly, a single primer/probe may result
in failure to recognize increasing viremia levels [18] and
even miss detections because of mismatches for HBV
DNA detection. Theoretically, the assay developed in this
study can detect all eight genotypes of HBV with the two
sets of primer/probe, especially the genotype A, B, C and
G of HBV which genome DNA can be matched by both
sets of primer/probe. Data from 69 serum samples from
patients with HBV infection showed that the duplex pri-
mer/probe assay developed for HBV DNA detection can
avoid mismatches between primer/probe and virus DNA
template to maximum extent. Of the confirmed 30 HBV
DNA positive samples, two HBV-samples failed to detect
by singleplex primer/probe set, but detected by duplex pri-
mer/probe set. The 2 sets of primers/probes used in our
assay could match interchangeably, creating additional
combinations with different primer-directed elongations.
Figure 2 shows the performances of the duplex primer/
probe and singleplex primer/probe assays in the testing of
the same serum sample. Obviously, the fluorescence value
of the 2 sets of primers/probes is higher than that of the
single set of primers/probes, and cycle threshold (Ct) can
shift towards left. As a result, the duplex primer/probe
Table 4 Reproducibility of the duplex real-time PCR assay
Reproducibility Target HBV
RNA (IU/ml)
Number of
determinations
Mean
Ct
SD CV
(%)
Intra-assay 10
5 10 24.15 0.24 0.83
10
4 10 27.09 0.34 1.07
10
2 10 33.31 0.49 1.25
Inter-assay 10
5 10 24.05 0.27 1.02
10
4 10 27.05 0.23 0.77
10
2 10 33.23 1.02 2.73
Figure 2 Comparison the duplex primer/probe real-time PCR assays with the singleplex primer/probe real-time PCR assays for HBV
DNA detection. The performances of the duplex primer/probe (C) and singleplex primer/probe (A, B) assays in the testing of the same serum
sample obtained from a patient with low HBV viraemia were compared. The red amplification curves represent FAM fluorescence signal and the
blue amplification curves represent Cy5 fluorescence signal. A: amplification plot of the HBV sample in the singleplex primer/probe A reaction
system. B: amplification plot of the HBV sample in the singleplex primer/probe B reaction system. C: amplification plot of the HBV sample in the
duplex primer/probe A and B reaction system. The Cy5 fluorescence signals indicate the amplification of IC. IC-A represents the amplification
plot of ICs used in the singleplex primer/probe A reaction system. IC-B represents the amplification plot of ICs used in the singleplex primer/
probe B reaction system. IC-C represents the amplification plot of ICs used in the duplex primer/probe A and B reaction system.
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HBV viraemia samples and increase the probability of
detection (Figure 2). The manufacturer’sl o w e rL O Do f
the CAP/CTM assay and Kehua HBV fluorescence detec-
tion kit are 12 IU/ml and 500 IU/ml, respectively. The
sensitivity and the specificity of the duplex assay were
comparable with the CAP/CTM assay and were superior
to domestic Kehua HBV fluorescence detection kit.
Furthermore, less serum samples (100 μls e r u m )a n d
lower cost were required than the CAP/CTM assay.
In order to identify PCR-inhibited samples, an
armored DNA was constructed as IC in PCR assays by
means of the overlapping extension PCR technique.
Unlike the plasmid-derived control which can only
monitor the amplification process, armored DNA was
co-extracted and co-amplified with the samples in the
same reaction tube that can monitor the entire real-time
PCR assay [23]. IC sequences were identical to the wild-
type HBV sequences, except that the probe binding site
sequences were replaced by the internal probe ones.
The 5’ ends of probes for the detection of HBV were
labelled with 6-carboxyfluorescein (FAM), while probe
for the detection of IC was labelled with cyanine dye
(Cy5), so that the amplification of the IC could be distin-
g u i s h e de a s i l yf r o mt h a to ft h eH B Vv i r u sb yd i f f e r e n t
fluorophore. In order to avoid its suppression to target
amplification, the concentration of competitive IC (CIC)
spiked into the samples was optimized at 1000 copies/ml
in the real-time assay (Table 2). Although with HBV
standards number at 5 × 10
5 IU/ml, the amplification of
the IC DNA (1000 copies/ml, Ct > 45) was competitively
inhibited. It does not affect the inclusion of an internal
control to monitor for false negative results due to DNA
degradation or to inhibitory factors potentially present in
clinical samples. By using this armored DNA as IC, false
negative samples that resulted from inappropriate
reagent additions in the tubes or the presence of PCR
inhibitors can be easily identified. Here, no inhibitors
were found in the clinical samples tested in the duplex
primer/probe assay.
Conclusions
We proved that two sets of primer/probe in the real-time
PCR assay can effectively resolve the problem of mis-
matches and avoid missing detections of HBV infection.
The established duplex real-time PCR assay is sufficiently
sensitive, specific, accurate, reproducible and cost-effective
for the detection of HBV DNA. It is suitable for high
throughput screening and frequent HBV DNA level moni-
toring. Nevertheless, this study was carried out in China
with a relatively small cohort, application of the duplex
real-time PCR assay might be validated by larger serum
samples including OHB serum samples.
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